Karen A. Fagan, MD

Karen A. Fagan, MD
Associate Professor
IM Pulmonary Medicine
Phone: (251) 471-7914
kfagan@usouthal.edu

EDUCATION

BA	University of California at San Diego 1988

MD	University of California at San Diego School of Medicine 1992

POST-DOCTORAL TRAINING

University of Texas Southwestern Medical School - Parkland Memorial Hospital
	Intern in Internal Medicine 1992-1993 Resident in Internal Medicine 1993-1995

University of Colorado Health Sciences Center
	Fellowship in Pulmonary Diseases and Critical Care 1995 - 1998 Pulmonary Sciences and Critical Care NIH Trainee 1996-1997 Cardiovascular Pulmonary Research Laboratory NIH Trainee 1997-1998

WORK EXPERIENCE

Chief, Pulmonary and Critical Care Division
	University of South Alabama, Mobile, AL

Associate Professor of Medicine 2008 to Present
	University of South Alabama, Mobile, AL

Associate Professor of Medicine 2004-2008
	University of Colorado Health Sciences Center, Denver, CO

Assistant Professor of Medicine 1999 – 2004
	University of Colorado Health Sciences Center, Denver, CO

Faculty Affiliate 2002-2005
	Department of Biomedical Sciences, Colorado State University, Fort Collins, CO

Instructor of Medicine 1998-1999
	University of Colorado Health Sciences Center, Denver, CO

Attending Physician 1998-2000
	Denver Health Medical Center, Denver, CO

HONORS / AWARDS

Outstanding Teacher, Pathophysiology Course, UCHSC School of Medicine

Pulmonary Pathophysiology Course Director 2005 and 2006

Western Society of Clinical Investigation elected 2004; Councilor 2006
Best Doctors in America selected 2003-2004, 2005-2006, 2007-2008
Howard Hughes Individual Investigator Award UCHSC 2002

Giles F. Filley Memorial Award for Excellence in Respiratory Physiology and

Medicine, American Physiological Society, 2001

Best Abstract Award, Council on Cardiopulmonary and Critical Care, American

Heart Association, 1997

School of Medicine Associates Award / Outstanding Graduate of the UCSD

School of Medicine, 1992

Outstanding Graduate, Third College, UCSD 1988

RESEARCH FUNDING

Active
RO1, Individual Investigator Award, 2003-2007(no-cost extension until 2009)
	NIH - NHLBI “Pulmonary Hypertension Following Intermittent Hypoxia” Role: Principal Investigator, 25% Effort, $225,000 per year


Established Investigator Award, 2003-2008
	American Heart Association “ET-1 and IL-6 in Pulmonary Hypertension” Role: Principal Investigator, 35% Effort $100,000 per year


Program Project Grant, 2003-2008
	NIH-NHLBI “Adaptations to Hypoxia” PI: Ivan McMurtry Role: Director, Animal Core, $1,420,000, Effort 10%


Program Project Grant, 2003-2008
	NIH-NHLBI “Adaptations to Hypoxia” PI: Ivan McMurtry Role: Co-Investigator, Project 1 (McMurtry PI), $1,420,000, Effort 10%


Post-Doctoral Training Grant, 2002-2007
	NIH-NHLBI T32 HL 07171-26 “Respiration and Circulation During Hypoxia” PI: Ivan McMurtry Role: Training Faculty, $308,688, No salary


Completed
KO8, Mentored Clinical Scientist Development Award, 1998-2003
	NIH - NHLBI “PO2 Modulation of NO and ET-1 in Pulmonary Hypertension” Role: Principal Investigator


Howard Hughes Individual Investigator Award, 2002
	Howard Hughes Medical Institute University of Colorado Health Sciences Center “Regulation of pulmonary vascular tone and structure following intermittent hypoxia” Role: Principal Investigator One-time Award, $25,000


Giles F. Filley Memorial Award, 2001
	American Physiologic Society “Pulmonary hypertension and differential expression of lung NOS in intermittent vs. continuous hypoxia”” Role: PI One-time Award, $25,000


R13, Conference Grant, 2006
	NIH-NHLBI "2006 Grover Conference on the Pulmonary Circulation" Role: Principal Investigator, $29,000 No salary

TRAINEES

Daniel J. Doran, MD, NIH Summer Student Fellowship 2001,
Currently resident in Anesthesiology, University of Washington, Seattle

Melinda Frye, DVM, Post-Doctoral Fellow, CVP Research Laboratory
PhD Candidate, Colorado State University, Awarded 2005
Co-mentor and Thesis committee member
Currently, Assistant Professor of Veterinary Medicine, Colorado State
University, Ft. Collins, CO

PUBLICATIONS

Papers

Fagan KA, Hepler LK, McMurtry IF, and DM Rodman. NO inhibits transgene expression in vascular smooth muscle cells. Chest (Supp) 114:85S, 1998

Fagan KA, Fouty BW, Tyler RC, Morris KG, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, and DM Rodman. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyper-responsive to mild hypoxia. J Clin Invest. 103(2):291-299, 1999

Fagan KA, Tyler RC, Sato K, Fouty BW, Morris KG, Huang PL, McMurtry IF, and DM Rodman. Relative contributions of endothelial, inducible and neuronal nitric oxide synthase to tone in the murine pulmonary circulation. Am J Phys. 277:L472-478, 1999

Geraci MW, Gao B, Shepard DC, Moore MD, Westcott JY, Alger LA, Fagan KA, Tuder RM, and NF Voelkel. Selective pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of hypoxic pulmonary hypertension. J Clin Invest. 103(11):1509-1515, 1999

Tyler RC, Fagan KA, Unfer RC, Gorman C, McClarrion M, Bullock C, and DM Rodman. Vascular inflammation inhibits gene transfer to the pulmonary circulation in vivo. Am J Phys. 277:L1199-1204, 1999

Wynne K, Fagan KA, and DB Badesch. Primary Pulmonary Hypertension. Women’s Health in Primary Care. 2:489-503, 1999

Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, Ei-Hag K, Elitok S, Bauer C,
Neumayer HH, Rodman DM, and F Theuring. Pulmonary fibrosis and lung inflammation in ET-1 transgenic mice. Am J Resp Cell Molec Biol 23:19-26, 2000

Fagan KA. McMurtry IF, and DM Rodman. Nitric Oxide Synthase in Pulmonary
Hypertension: Lessons from Knockout Mice. (Invited Review) Physiological Research. 49:539-45, 2000

Maloney JP, Halbower AC, Fouty BF, Fagan KA, Balasubramaniam V, Pike A, Fennessy P, and M Moss. Systemic absorption of enteral feeding dye during critical illness. New Eng J Med. 343(14)1047-8, 2000

Fagan KA, McMurtry IF, and DM Rodman. Role of Endothelin-1 in Lung Disease. (Invited Review) Respiratory Research. 2:90-101, 2001

Fujita M, Shannon JM, Irvin CG, Augustin A, Fagan KA, and RJ Mason. Overexpression of TNF-alpha in the lungs produces pulmonary hypertension and a physiologic phenotype consistent with emphysema. Am J Phys. 280:L39-L49, 2001

Fagan KA. Highlighted Topics: Physiological and Genomic Consequences of Intermittent Hypoxia: Selected Contribution: Pulmonary hypertension in mice following intermittent hypoxia. J App Phys. 90:2502-2507, 2001

Fagan KA, Morissey B, Fouty BW, Sato K, Wright Harral J, Morris KG, Miller M, Vidmar S, McMurtry IF, and DM Rodman. Upregulation of nitric oxide synthase following chronic hypobaric hypoxia in mice with severe pulmonary hypertension. Respiratory Research. 2: 306-313, 2001

Fagan KA and JV Weil. Potential genetic contributions to control of the pulmonary circulation and ventilation at high altitude. (Invited Review) High Altitude Medicine. 2: 165-171, 2001

Fouty BW, Grimison B, Fagan KA, Le Cras, TD, Wright Harral J, Hoedt-Miller M, Sclafani RA, and DM Rodman. Central role for p27-kip1 in modulating pulmonary artery smooth muscle cell proliferation. Submitted, Am J Resp Cell Molec Biol, 25: 652-658, 2001

Fujita M, Mason RJ, Cool C, Shannon JM, Hara N, and Fagan KA. Pulmonary hypertension in TNF-a-overexpressing mice is associated with decreased VEGF gene expression. J App Phys, 93:2162-2170, 2002

Fagan KA and DB Badesch. Pulmonary Hypertension Associated with Connective Tissue Disease (Invited Review). Progress in Cardiovascular Diseases, 45:225-34, 2002

Fagan KA, DH Collier, and DB Badesch, Scleroderma Associated Pulmonary Hypertension. (Invited Review). Advances in Pulmonary Hypertension, 1(2): 5-9, 2002

Littler CM, Morris KG, Fagan KA, McMurtry IF, Messing RO and EC Dempsey. Protein Kinase C Epsilon Null Mice Have Decreased Hypoxic Pulmonary Vasoconstriction. Am J Phys, 284(4):H1321-31, 2003

Le Cras TD, Hardie WD, Pyles DB, Fagan KA, Whitsett JA, and TR Korfhagen.
Transforming growth factor-alpha causes pulmonary vascular disease through autocrineparacrine signaling in distal epithelial cells. Am J Phys, 285: L1043-1054, 2003

Fagan KA, Collier DH, and DB Badesch. Scleroderma and Pulmonary Hypertension. Rev Bras Reumatol, 43(5):294-301, 2003

McMurtry IF, Bauer NR, Fagan KA, Nagaoka T, Gebb SA, and M Oka. Hypoxia and Rho/Rho-Kinase Signaling: Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol, 543:127-37, 2003

Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG , and IF McMurtry.
Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary
hypertension in mice by inhibition of Rho-kinase. Am J Phys, 287:L656-664, 2004

West J, Fagan KA, Steudel W, Fouty B, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, and DM Rodman. Transgenic Mice expressing a human BMPRII mutation in vascular smooth muscle develop pulmonary arterial hypertension. Circ Res, 94:1109-1114. 2004

West J, Buchholz M, Fierro A, Y Tada, Fagan K, and DM Rodman. Adenoviral gene transfer to the neonatal rat pulmonary circulation. J Gene Med, 6:734-9 2004

Hartsfield CL, McMurtry IF, Ivy DD, Morris KG, Vidmar S, Rodman DM and KA Fagan. Cardioprotective and vasomotor effects of HO activity during acute and chronic hypoxia. Am J Phys, 287LH2009-2015, 2004

Bull TM, Fagan KA, and DB Badesch. Pulmonary hypertension: The latest treatments. J Resp Dis. 25:242-253, 2004

Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, and M Oka. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Resp Crit Care Med. 171:494-499. 2005

Rodman DM, Reese K, Harral J, Fouty B, Wu S, West J, Hoedt-Miller M, Tada Y, Li KX, Cool C, Fagan K, Cribbs L. Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res. Apr 29;96(8):864-72. 2005

Fagan KA, Bull TM,. Badesch DB, and NF Voelkel. Metastatic Cancer While on Continuous Prostacyclin Therapy. Chest, 128: 619-620S, 2005

Fagan KA. Potential Genetic Contributions to Nonidiopathic, Nonfamilial Pulmonary Hypertension. (Invited Review) Advances in Pulmonary Hypertension, 4(1):24-28, 2005

Golembeski, SM West, Tada Y, and KA Fagan. IL-6 causes Mild Pulmonary Hypertension and Augments Hypoxia-Induced Pulmonary Hypertension in Mice, Chest, 128:572-573S, 2005

Littler CM, Wehling CA, Wick MJ, Fagan KA, Cool CD, Messing RO, Dempsey EC. Divergent Contractile And Structural Responses Of The Murine PKC-Epsilon Null Pulmonary Circulation To Chronic Hypoxia. Am J Phys. 289: L1083-1093, 2005

Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am. (3):451-64. 2005

Golembeski S, Schmidt P, Dovico S, Gebb SA, and KA Fagan. Oxidative stress and decreased NO activity in intermittent hypoxia-induced pulmonary hypertension. In review, 2007

Dovico S, Ickes B, Schmidt P,Golembeski SM, West J, and KA Fagan. IL-6 causes pulmonary hypertension, vascular remodeling, and pulmonary artery smooth muscle cell proliferation through activation of Jak/Stat signalling. In review, 2007

Stenmark K, Fagan KA, and M Frid. Hypoxic Pulmonary Vascular Remodeling: Cellular and Molecular Mechnanisms. (Invited Review) Circ Res. 99:675-91. 2006

Hagen M , Steudel W, Carr M, Lane K, Fagan K, Rodman D, J West. Interaction of Interleukin-6 and the BMP Pathway in Pulmonary Smooth Muscle and Endothelium. Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1473-9. 2007

Irwin D, Helm K, Campbell N, Imamura M, Fagan KA, Harral J, Carr M, Young KA, Klemm D, Gebb S, Dempsey EC, West J, Majka S. Neonatal lung side population cells demonstrate endothelial potential and are altered in response to hyperoxia-induced lung simplification. Am J Physiol Lung Cell Mol Physiol. Oct;293(4):L941-51. 2007

Oka M, Karoor V, Nagaoka T, Sakao E, Limbird J, Imamura M, Gebb SA, Fagan KA, and IF McMurtry. Dehydroepiandersteone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension in rats. Cardiovasc Res. Jun 1;74(3):377-87. 2007

Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol. Jun 9. 2008
Frei AC, Guo Y, Jones DW, Pritchard KA Jr, Fagan KA, Hogg N, Wandersee NJ. Vascular dysfunction in a murine model of severe hemolysis. Blood. Jul 15;112(2):398-405. 2008

Homma N, Nagaoka T, Karoor V, Imamura M, Taraseviciene-Stewart L, Walker LA, Fagan KA, McMurtry IF, Oka M. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol. Jul;295(1):L71-8. 2008

West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, and Fagan K. Mice Expressing BMPR2 Transgene in Smooth Muscle Develop Pulmonary Vascular Lesions. Accepted, Am J Physiol Lung Cell Mol Physiol, 8/ 2008

Chapters

Fagan KA and DB Badesch. Pulmonary Hypertension. In Cardiology Secrets, Second Edition, Hanley and Bufus, USA. 2001

Fagan KA and TE King. Lymphocytic Interstitial Pneumonia. Up-To-Date in Pulmonary Medicine. CD Rom. USA. 1997-2004

Fagan KA. Taking the Pulmonary History. Pulmonary and Respiratory Care Secrets. Second Edition Hanley and Bufus. USA. 2002

Fagan KA. Pulmonary Arterial Hypertension. In Current Diagnosis and Treatment in Pulmonary Disease. Ed ME Hanley and CH Welsh. McGraw-Hill, USA 2003

McMurtry IF, Bauer NR, Fagan KA, Nagaoka T, Gebb SA, and M Oka. Hypoxia and Rho/Rho-Kinase Signaling: Lung development versus hypoxic pulmonary hypertension. Hypoxia: Through the life cycle. Ed RC Roach, et al, Kluwer Academin/Plenum Publishers. 2004

Fagan KA and DB Badesch. Pulmonary Hypertension in Association with Connective Tissue Disease. Pulmonary Circulation, 2nd Ed. Eds L Rubin and A Peacock , Arnold Press, London, England, 2004

Fagan KA and IF McMurtry, Pulmonary Vascular Pharmacology, in Murray and Nadel’s Textbook of Respiratory Medicine, 2005

VISITING PROFESSOR / INVITED SPEAKER

University of Texas Southwestern Medical School, 1998
Emory University, 1999
Johns Hopkins University, 2000
University of Wyoming, 2001
Brown University, 2003
American Thoracic Society Meeting, Invited Symposium Speaker, 2004, 2005
Palliative Care / End of Life Issues Conference, University of Colorado Hospital, 2006
Case Western Reserve University, 2007
University of South Alabama, 2007
Tufts New England Medical Center, 2007

CLINICAL ACTIVITIES

Denver Health Medical Center, 1998-2000
	Attending Physician, Pulmonary Consult Service and Outpatient Clinic
University of Colorado Hospital 1998 - 2008
	Attending Physician, Medical Intensive Care Unit, Pulmonary Consult Service, Pulmonary Hypertension Center, Pulmonary Clinics
University of South Alabama Medical Center 2008-Present
	Attending Physician, Medical Intensive Care Unit, Pulmonary Consult Service, Pulmonary Hypertension Center, Pulmonary Clinics

TEACHING ACTIVITIES

Medical Student Teaching:
	Medicine 6000, Course Director Pulmonary Pathophysiology, 2004 to 2005
	Pulmonary Pathophysiology Course for second year medical students Responsible for curriculum organization, primary lecturing, student examinations, course syllabus, etc.


	Essentials Curriculum Pulmonary Sub-Block Director, 2006 - 2008
	Pulmonary Core Block Course in new medical school curriculum for first year medical students (only pulmonary course in curriculum) Responsible for curriculum organization, lecturing, student examinations, course syllabus, etc.


	Foundations of Doctoring, 1999-2003
	Physical Exam Instructor for First Year Medical Students Hidden Curriculum leader for 4th year Medical Students Preceptor for 3rd year medical student, Daniel Doran


	Mentor, NIH Summer Student Research Program, 2001
	Daniel Doran, MS I


PhD Advisory Committee, Colorado State University, Ft. Collins:
	Candidate, Melinda Frye, DVM, 2002-2005


Intern and Resident Teaching, Univ. Colorado Department of Medicine:
	Noon and AM lecture series for medicine residents, 1997 to 2008 Clinical Pathologic Conference, Faculty Lecturer 1999 Morning Report, 2001-2002


Intern and Resident Teaching, Univ. South Alabama Department of Medicine:
	Noon Conference, 2008 to Present Morning Report, 2008 to Present


Fellow Teaching Univ. Colorado:
	Morning conferences, 2000-2008 Critical Care Lecture series 2004 - 2008 Pulmonary Grand Rounds, 1998 to 2008 Training Faculty, NIH Post-doctoral Training Grant, Cardiovascular Pulmonary Research Laboratory, Co-Mentor, Post-doctoral fellow, Melinda Frye, DVM, 2002 to 2005


Fellow Teaching Univ. South Alabama:
	Core Curriculum 2008 to Present Translational and Critical Care Conferences 2008 to Present


Continuing Medical Education / Outreach Education:
	Chest Conference, St. Joseph’s Hospital, Denver, CO, 2000 University of Colorado Outreach Education, 2000-2002 CME of the Rockies Faculty, 2002 Sacred Heart Health Systems, Pensacola, FL 2008


Medical Grand Rounds University of South Alabama
	"Occupational and Environmental Lung Disease" May 2008 "Cough" August 2008

SERVICE / PROFESSIONAL ORGANIZATIONS / ACTIVITIES

Professional Societies / Participation:

American Thoracic Society

Chair-Elect, Program Committee Pulmonary Circulation Assembly 2008-2009
International Conference Committee 2008-2009
Program Committee, Pulmonary Circulation Assembly, 2000 - present
Planning Committee, Pulmonary Circulation Assembly, 2001 - 2003, 2006-2008
Nominating Committee, Pulmonary Circulation Assembly, 2002-2003 and
2005-2006
Womens’ Mentoring Program, Mentee, 2002-2003
ATS National Membership Committee, 2004-2005, 2005-2006, 2006-2007
Mentoring subcommittee, 2005-2006, 2007-2008, 2008-2009

American Heart Association

Council on Cardiopulmonary, Perioperative and Critical Care, Leadership
Committee, Member-at-large, 2004-2008

American Physiological Society

Minority Mentoring Program, 2001

American College of Chest Physicians

Leadership Development Conference, 1999

Pulmonary Hypertension Association

Scientific Leadership Council 2004-2008
Member, Research Committee, 2004-2008
Chair, Scientific Sessions, 2008

Western Society of Clinical Investigation

Chair, Pulmonary Sessions, Western Regional Meeting WSCI, AMFR 2006
Councilor, 2006-2008

Grant Review Panels:

Lung, Respiration, and Resuscitation Study Section, American Heart Association,
National Center Review Committee 2002-2008
Chairperson 2006-2007, 2007-2008
NIH NRSA Pre and Post-doctoral Fellowship Study Section 2004-2007
NIH Special Emphasis Panel, Sickle Cell Disease Research Networks 2005
Burroughs Wellcome Trust 2004

Journal Editorship, Reviewer:

Associate Editor, Advances in Pulmonary Hypertension, 2004-2006

Publication Reviewer:	American Journal of Physiology Journal of Applied Physiology Respiratory Research American Journal of Respiratory Cell and Molecular Biology American Journal of Respiratory and Critical Care Medicine Journal Topics, ATS Pulmonary Circulation Assembly Web Site European Respiratory Journal Pulmonary Pharmacology and Therapeutics

National / International Meetings Service / Organization:

Facilitator:

Thomas Petty Aspen Lung Conference 2001, 2004, 2005, 2006
Pulmonary Hypertension Association Meeting 2002, 2004, 2006, 2008
American Thoracic Society Meetings 2001 – 2008
Symposium Organizer, 2001

Co-director, Treasurer, Thomas Petty Aspen Lung Conference 2004-2008
Co-Chair, Thomas Petty Aspen Lung Conference, 2004
Chair, Grover Conference on the Pulmonary Circulation, 2006
Speaker, Pulmonary Hypertension Association International Conference, 2002, 2004, 2006, 2008
Speaker, Patient Support Groups, Pulmonary Hypertension Association, Denver. Colorado Springs, and Albuquerque Chapters, 2001 – 2008

University of Colorado Health Sciences Center Service / Committee Memberships:

Pulmonary and Critical Care Medicine Junior Faculty Retreat Organizer, 2002

Fellowship Recruitment Committee – University of Colorado Division of Pulmonary Sciences and Critical Care Medicine 1999 – present

UCHSC Campus-Wide Research Strategic Planning Committee 2002-2003

University of Colorado Hospital

Intensive Care Unit Quality Assurance Committee 2004-2008
Operative and Other Procedures Committee 2004 to 2008
Chair 2006-2008

University of South Alabama College of Medicine and Medical Center

ICU Committee 2008
Department of Medicine Education Committee 2008
Student Research Committee 2008
Graduate Medical Education Committee 2008

PROFESSIONAL CERTIFICATION

American Board of Medical Examiners Completed 1993
American Board of Internal Medicine Certificate(s) Number 165436

	Diplomat in Internal Medicine 1995-2005 Recertified 2005-2015 Diplomat in Pulmonary Disease 1998-2007 Recertified 2007-2017 Diplomat in Critical Care 1999-2009 Recertified 2009-2019

LICENSES

Alabama Medical License # 28767 Current through 12/31/2008
Alabama Controlled Substance # 28767 Current through 12/31/2008
Colorado Medical License # 33695 Current through 5/2009
DEA Certificate # BF4845307 Current through 9/2010